Literature DB >> 12576923

Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.

Peter Attia1, Giao Q Phan, Paul H Duray, Steven A Rosenberg.   

Abstract

Hypercalcemia associated with malignancy has been attributed to osteolytic processes secondary to bony metastases and to humoral factors causing increased bone resorption and decreased renal excretion of calcium. Parathyroid hormone-related protein (PTH-rP) is a humoral factor that has been associated with hypercalcemia in renal cell carcinoma, squamous cell carcinoma, and bladder carcinoma. Hypercalcemia does occur in patients with melanoma; however, few studies have reported on hypercalcemia in these patients, and even fewer have described a direct connection to PTH-rP. We here report a patient with stage IV malignant melanoma presenting with severe hypercalcemia associated with elevated PTH-rP levels. Immunohistochemistry showed strong expression of PTH-rP in biopsy of the patient's subcutaneous masses. In addition, we found a 4.9% incidence of hypercalcemia in 1,146 consecutive patients treated for metastatic melanoma at the Surgery Branch of the National Cancer Institute between January 1, 1988 and March 31, 2000. Thus, PTH-rP may play a significant role in severe hypercalcemia in patients with metastatic melanoma. The discovery of PTH-rP and relevant literature will also be reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576923      PMCID: PMC2562280          DOI: 10.1097/00000421-200302000-00009

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  13 in total

1.  Hypercalcemia and malignant melanoma.

Authors:  I Levy; L Feun
Journal:  Am J Clin Oncol       Date:  1990-12       Impact factor: 2.339

Review 2.  Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide.

Authors:  A E Broadus; M Mangin; K Ikeda; K L Insogna; E C Weir; W J Burtis; A F Stewart
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

3.  Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases.

Authors:  D Powell; F R Singer; T M Murray; C Minkin; J T Potts
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

4.  Hypercalcemia and malignant melanoma.

Authors:  M E Burt; M F Brennan
Journal:  Am J Surg       Date:  1979-06       Impact factor: 2.565

5.  Parathyroid hormone-related protein purified from a human lung cancer cell line.

Authors:  J M Moseley; M Kubota; H Diefenbach-Jagger; R E Wettenhall; B E Kemp; L J Suva; C P Rodda; P R Ebeling; P J Hudson; J D Zajac
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

6.  Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.

Authors:  S B Rodan; K L Insogna; A M Vignery; A F Stewart; A E Broadus; S M D'Souza; D R Bertolini; G R Mundy; G A Rodan
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

7.  Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia.

Authors:  E L Simpson; G R Mundy; S M D'Souza; K J Ibbotson; R Bockman; J W Jacobs
Journal:  N Engl J Med       Date:  1983-08-11       Impact factor: 91.245

8.  Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer.

Authors:  W J Burtis; T G Brady; J J Orloff; J B Ersbak; R P Warrell; B R Olson; T L Wu; M E Mitnick; A E Broadus; A F Stewart
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

9.  Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma.

Authors:  S A Berson; R S Yalow
Journal:  Science       Date:  1966-11-18       Impact factor: 47.728

10.  Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer.

Authors:  B L Riggs; C D Arnaud; J C Reynolds; L H Smith
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

View more
  2 in total

1.  Serum calcium, albumin and tumor stage in cutaneous malignant melanoma.

Authors:  Mridul Datta; Paul Savage; James Lovato; Gary G Schwartz
Journal:  Future Oncol       Date:  2016-06-16       Impact factor: 3.404

2.  Complications of bone metastases from malignant melanoma.

Authors:  Jamal Zekri; Maria Marples; Dominic Taylor; Kiran Kandukurti; Lucy McParland; Janet E Brown
Journal:  J Bone Oncol       Date:  2017-08-18       Impact factor: 4.072

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.